Key result
rs1333049 C allele is linked to ~49% higher risk of recurrent MI or cardiac death post-ACS.
Why the study?
The contribution of the rs1333049 variant on chromosome 9p21 to recurrent myocardial infarction or cardiac death after acute coronary syndrome was unclear.
Does the rs1333049 variant on chromosome 9p21 increase the risk of recurrent MI or cardiac death in patients with acute coronary syndrome?
Observational (n=8,718)
Yes
Does the rs1333049 variant on chromosome 9p21 increase the risk of recurrent MI or cardiac death in patients with acute coronary syndrome?
Hazard Ratio: 1.49 (95% CI 1.03–1.98)
p-value: p=0.028
The 9p21 genetic variant rs1333049 is independently associated with an increased risk of recurrent MI or cardiac death within 6 months after an acute coronary syndrome, and its inclusion improves the GRACE risk score classification.
Should not yet change post-ACS management; hypothesis-generating for genetic risk stratification in secondary prevention.
AIMS: Recent genetic studies identified the rs1333049 variant on chromosome 9p21 as a major susceptibility locus for coronary artery disease and myocardial infarction (MI). Here, we evaluated whether this variant also contributes to recurrent MI or cardiac death following an acute coronary syndrome (ACS). METHODS AND RESULTS: A total of 3247 patients with ACS enrolled in the Global Registry of Acute Coronary Events (GRACE) in three distinct populations (UK, Belgium and Poland) were prospectively followed for 6 months and genotyped for rs1333049, in addition to 3004 and 2467 healthy controls from the UK and Belgium. After having confirmed that the at-risk C allele of rs1333049 was associated with index ACS in the UK and Belgian populations, we found that the rs1333049 at-risk C allele was significantly and independently associated with recurrent MI [age- and gender-adjusted hazard ratio (HR) 1.48, CI = 1.00-2.19, P = 0.048; and multivariable-adjusted HR 1.47, CI = 0.99-2.18; P = 0.053] and with recurrent MI or cardiac death (age- and gender-adjusted HR 1.58, CI = 1.00-2.48; P = 0.045; and multivariable adjusted HR 1.49, CI = 1.03-1.98; P = 0.028) within 6 months after an index ACS. Inclusion of rs1333049 into the GRACE risk score significantly improved classification for recurrent MI or cardiac death (P = 0.040), as calculated by the integrated discrimination improvement method. CONCLUSION: In this large observational study, the 9p21 variant was independently associated with adverse cardiac outcome after ACS.
No takes yet. Share an insight, caveat, or question.
Buysschaert et al. (2010) conducted an observational in Acute coronary syndrome (n=8,718). rs1333049 at-risk C allele on chromosome 9p21 vs. Non-carriers was evaluated on Recurrent MI or cardiac death (HR 1.49, 95% CI 1.03-1.98, p=0.028). The rs1333049 at-risk C allele was independently associated with recurrent MI or cardiac death within 6 months after an acute coronary syndrome (HR 1.49; 95% CI 1.03-1.98; P=0.028).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: